GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: AL-001 | AL001
Compound class:
Antibody
Comment: Latozinemab (AL001) is an anti-sortilin 1 (SORT1) monoclonal antibody. It is proposed to elevate progranulin levels by inhibiting the SORT1-mediated degradation pathway for progranulin (PGRN). This mechanism is being investigated as a disease‐modifying therapy for patients with frontotemporal dementia caused by loss-of-function mutations in GRN.
|
| No information available. |
Summary of Clinical Use  |
| Latozinemab (AL001) is being investigated in clinical trials to determine safety and efficacy for the treatment of neurodegenerative diseases and wet age-related macular degeneration (wAMD). In February 2024, the FDA granted latozinemab breakthrough therapy designation as a treatment for frontotemporal degeneration (frontotemporal dementia). |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT03987295 | A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2) | Phase 2 Interventional | Alector Inc. | ||
| NCT06111014 | Continuation Study for Latozinemab | Phase 3 Interventional | Alector Inc. | ||
| NCT04374136 | A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3) | Phase 3 Interventional | Alector Inc. | The INFRONT-3 study | |
| NCT03636204 | A First in Human Study in Healthy Volunteers and in Participants With Frontotemporal Dementia With Granulin (GRN) Mutation | Phase 1 Interventional | Alector Inc. | 1 | |
